Tricida Inc (NASDAQ:TCDA) Expected to Post Earnings of -$0.89 Per Share

Share on StockTwits

Equities research analysts expect Tricida Inc (NASDAQ:TCDA) to post earnings per share of ($0.89) for the current quarter, Zacks reports. Zero analysts have made estimates for Tricida’s earnings. The lowest EPS estimate is ($0.94) and the highest is ($0.83). Tricida reported earnings per share of ($0.66) in the same quarter last year, which suggests a negative year-over-year growth rate of 34.8%. The company is expected to announce its next quarterly earnings report after the market closes on Thursday, November 14th.

According to Zacks, analysts expect that Tricida will report full-year earnings of ($3.53) per share for the current year, with EPS estimates ranging from ($3.65) to ($3.40). For the next year, analysts forecast that the business will report earnings of ($3.73) per share, with EPS estimates ranging from ($4.10) to ($3.35). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Tricida.

Tricida (NASDAQ:TCDA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.12.

A number of brokerages have recently commented on TCDA. Needham & Company LLC set a $50.00 target price on Tricida and gave the stock a “buy” rating in a report on Monday, August 12th. Cowen set a $50.00 target price on Tricida and gave the stock a “buy” rating in a report on Tuesday, October 15th. Zacks Investment Research upgraded Tricida from a “sell” rating to a “hold” rating in a report on Thursday, October 10th. Finally, ValuEngine upgraded Tricida from a “sell” rating to a “hold” rating in a report on Friday, October 11th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Tricida has an average rating of “Buy” and a consensus target price of $49.60.

In related news, Director Robert J. Alpern sold 1,832 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $38.98, for a total transaction of $71,411.36. Also, CEO Gerrit Klaerner sold 10,255 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $30.69, for a total value of $314,725.95. In the last quarter, insiders sold 81,926 shares of company stock valued at $2,782,523. Company insiders own 66.70% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of TCDA. Price T Rowe Associates Inc. MD boosted its holdings in Tricida by 69.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,901,325 shares of the company’s stock valued at $153,946,000 after acquiring an additional 1,603,231 shares during the period. Vanguard Group Inc. boosted its holdings in Tricida by 49.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,246,304 shares of the company’s stock valued at $88,639,000 after acquiring an additional 740,141 shares during the period. Vivo Capital LLC boosted its holdings in Tricida by 82.4% during the 2nd quarter. Vivo Capital LLC now owns 1,424,525 shares of the company’s stock valued at $56,212,000 after acquiring an additional 643,340 shares during the period. JPMorgan Chase & Co. boosted its holdings in Tricida by 47.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,500,373 shares of the company’s stock valued at $57,314,000 after acquiring an additional 486,178 shares during the period. Finally, BlackRock Inc. boosted its holdings in Tricida by 23.4% during the 2nd quarter. BlackRock Inc. now owns 2,356,417 shares of the company’s stock valued at $92,984,000 after acquiring an additional 447,562 shares during the period. Institutional investors own 80.67% of the company’s stock.

Shares of NASDAQ TCDA traded down $0.30 during trading on Thursday, hitting $38.98. The company had a trading volume of 131,700 shares, compared to its average volume of 263,408. The firm has a market capitalization of $1.95 billion, a P/E ratio of -8.40 and a beta of 0.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 14.22 and a current ratio of 14.23. The stock has a 50 day simple moving average of $34.20 and a 200 day simple moving average of $34.43. Tricida has a 12 month low of $19.43 and a 12 month high of $42.80.

Tricida Company Profile

Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.

Read More: Leveraged Buyout (LBO)

Get a free copy of the Zacks research report on Tricida (TCDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.